Prime Minister Narendra Modi will on Saturday visit the Pune-based Serum Institute of India, which has partnered with global pharma giant AstraZeneca and the Oxford University for COVID-19 vaccine, a senior official said on Thursday.
The Central Drug Standard Control Organisation has granted permission for manufacture of COVID-19 vaccine for pre-clinical test, examination and analysis to seven firms, two of which are the Serum Institute of India (SII) and the Gennova Biopharmaceuticals.
"We have received a confirmation about PM Modi's visit to the Serum Institute of India on Saturday, but his minute-to -minute program is yet to be received," Pune Divisional Commissioner Saurabh Rao said.
On Tuesday, Rao said there was a possibility of the PM's visit to Pune, and if that happens, it would be aimed at reviewing the status of the vaccine candidate for coronavirus infection and to know about its launch, production and distribution mechanisms.
Rao had also informed that ambassadors and envoys from 100 countries will visit the Serum Institute of India and the Gennova Biopharmaceuticals Ltd here on December 4.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU